Cognivia Expands Its Portfolio of Predictive Solutions Introducing Compl-AI, an Innovative Solution That Predicts the Risk of Patient Nonadherence & Dropout

Cognivia, a clinical trial technology company that combines machine learning with a sophisticated evaluation of patient characteristics and traits, is proud to announce the launch of its latest innovation: Compl-AI.

Compl-AI is a predictive tool that helps clinical trial sponsors optimize patient recruitment and engagement strategies. Nonadherence in clinical trials and high rates of dropout make efficacy and safety more difficult to determine. Compl-AI gets in front of this common challenge by scoring patient behavior at screening using machine learning. The Compl-AI patient behavior score enables individualized patient engagement strategies. Beyond clinical research, Compl-AI offers healthcare providers a unique approach to tailor and optimally adjust their patient support for better treatment adherence.

AiThority: The 3 Building Blocks to Make AI Accessible

“Cognivia is dedicated to cracking the code on the complex relationship between patient traits and behavior,” said CEO Dominique Demolle, PhD. “Individual patient characteristics and experiences have a significant impact on clinical trial data. With Compl-AI, we are excited with the potential to personalize patient engagement strategies and continue to push drug development into a new frontier.”

Using Compl-AI, sponsors can detect the risk of non-compliance and drop out risk before the start and monitor it over the course of their clinical trial. To learn more about how Compl-AI works and the advantages of this innovative approach, join CEO Dominique Demolle, PhD, and COO Chantal Gossuin

Read More: How ChatGPT Will Transform Customer Service

[To share your insights with us, please write to sghosh@martechseries.com]